• +1-646-491-9876
    • +91-20-67278686

    Search

    Mantle Cell Lymphoma - Pipeline Review, H1 2015

    Mantle Cell Lymphoma - Pipeline Review, H1 2015

    • Report Code ID: RW0001172452
    • Category Pharmaceuticals
    • No. of Pages 336
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Mantle Cell Lymphoma-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Mantle Cell Lymphoma-Pipeline Review, H1 2015', provides an overview of the Mantle Cell Lymphoma's therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 7
    Introduction 8
    Global Markets Direct Report Coverage 8
    Mantle Cell Lymphoma Overview 9
    Therapeutics Development 10
    Pipeline Products for Mantle Cell Lymphoma-Overview 10
    Pipeline Products for Mantle Cell Lymphoma-Comparative Analysis 11
    Mantle Cell Lymphoma-Therapeutics under Development by Companies 12
    Mantle Cell Lymphoma-Therapeutics under Investigation by Universities/Institutes 16
    Mantle Cell Lymphoma-Pipeline Products Glance 17
    Late Stage Products 17
    Clinical Stage Products 18
    Early Stage Products 19
    Mantle Cell Lymphoma-Products under Development by Companies 20
    Mantle Cell Lymphoma-Products under Investigation by Universities/Institutes 24
    Mantle Cell Lymphoma-Companies Involved in Therapeutics Development 25
    AbbVie Inc. 25
    Accentia Biopharmaceuticals, Inc. 26
    Actinium Pharmaceuticals, Inc. 27
    Advancell 28
    Affimed Therapeutics AG 29
    Amgen Inc. 30
    Astellas Pharma Inc. 31
    Astex Pharmaceuticals, Inc. 32
    Bayer AG 33
    Bristol-Myers Squibb Company 34
    Celgene Corporation 35
    Celldex Therapeutics, Inc. 36
    Eisai Co., Ltd. 37
    Eli Lilly and Company 38
    EpiZyme, Inc. 39
    Gilead Sciences, Inc. 40
    GlaxoSmithKline plc 41
    ImmunoGen, Inc. 42
    Incyte Corporation 43
    Infinity Pharmaceuticals, Inc. 44
    Johnson & Johnson 45
    Karyopharm Therapeutics, Inc. 46
    Kite Pharma, Inc. 47
    MedImmune, LLC 48
    Merck & Co., Inc. 49
    Millennium Pharmaceuticals, Inc. 50
    MorphoSys AG 51
    Nordic Nanovector AS 52
    Novartis AG 53
    Onconova Therapeutics, Inc. 54
    Onyx Pharmaceuticals, Inc. 55
    Pfizer Inc. 56
    Pharmacyclics, Inc. 57
    Portola Pharmaceuticals, Inc. 58
    Seattle Genetics, Inc. 59
    Sevion Therapeutics, Inc. 60
    Stemline Therapeutics, Inc. 61
    Teva Pharmaceutical Industries Limited 62
    TG Therapeutics, Inc. 63
    Mantle Cell Lymphoma-Therapeutics Assessment 64
    Assessment by Monotherapy Products 64
    Assessment by Combination Products 65
    Assessment by Target 66
    Assessment by Mechanism of Action 69
    Assessment by Route of Administration 72
    Assessment by Molecule Type 74
    Assessment by Molecule Type 74
    Drug Profiles 76
    13197-Drug Profile 76
    abemaciclib-Drug Profile 78
    abexinostat hydrochloride-Drug Profile 79
    acadesine-Drug Profile 81
    ACP-196-Drug Profile 83
    AFM-11-Drug Profile 84
    agatolimod sodium-Drug Profile 85
    alisertib-Drug Profile 88
    AMG-319-Drug Profile 92
    AT-7519-Drug Profile 93
    bendamustine hydrochloride-Drug Profile 96
    Betalutin-Drug Profile 99
    blinatumomab-Drug Profile 101
    BLyS-gel-Drug Profile 104
    BMS-986016-Drug Profile 105
    bortezomib-Drug Profile 106
    buparlisib hydrochloride-Drug Profile 112
    carfilzomib-Drug Profile 116
    CC-122-Drug Profile 120
    Cell Therapy for Oncology-Drug Profile 122
    Cell Therapy to Target CD19 for Oncology-Drug Profile 123
    Cell Therapy to Target CD19 for Oncology-Drug Profile 124
    Cell Therapy to Target CD20 for Chemotherapy Resistant Cancers-Drug Profile 125
    CEP-9722-Drug Profile 126
    cerdulatinib-Drug Profile 127
    copanlisib-Drug Profile 128
    dasiprotimut-T-Drug Profile 131
    denintuzumab mafodotin-Drug Profile 133
    duvelisib-Drug Profile 134
    E-7449-Drug Profile 136
    EPZ-015666-Drug Profile 137
    FROST-400-Drug Profile 138
    GS-9973-Drug Profile 139
    ibrutinib-Drug Profile 140
    ibrutinib + ublituximab + TGR-1202-Drug Profile 146
    idelalisib-Drug Profile 147
    IMGN-529-Drug Profile 150
    INA-01-Drug Profile 151
    INCB-39110-Drug Profile 152
    INCB-40093-Drug Profile 154
    ixazomib citrate-Drug Profile 155
    KTE-C19 CAR-Drug Profile 158
    lenalidomide-Drug Profile 160
    MEDI-0680-Drug Profile 164
    MEDI-551-Drug Profile 165
    MGD-011-Drug Profile 167
    Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies-Drug Profile 168
    Monoclonal Antibody Conjugate to Target CD45 for Oncology-Drug Profile 169
    MOR-208-Drug Profile 170
    moxetumomab pasudotox-Drug Profile 172
    ON-123300-Drug Profile 174
    palbociclib-Drug Profile 175
    pevonedistat hydrochloride-Drug Profile 179
    ribociclib-Drug Profile 181
    selinexor-Drug Profile 184
    SGN-CD70A-Drug Profile 188
    SL-101-Drug Profile 189
    SNS-01T-Drug Profile 190
    sotrastaurin acetate-Drug Profile 191
    TGR-1202-Drug Profile 193
    tisagenlecleucel-T-Drug Profile 195
    tretinoin-Drug Profile 197
    ublituximab-Drug Profile 198
    varlilumab-Drug Profile 200
    venetoclax-Drug Profile 202
    vorinostat-Drug Profile 205
    Mantle Cell Lymphoma-Recent Pipeline Updates 209
    Mantle Cell Lymphoma-Dormant Projects 314
    Mantle Cell Lymphoma-Discontinued Products 316
    Mantle Cell Lymphoma-Product Development Milestones 317
    Featured News & Press Releases 317
    Appendix 330
    Methodology 330
    Coverage 330
    Secondary Research 330
    Primary Research 330
    Expert Panel Validation 330
    Contact Us 330
    Disclaimer 331

    List of Tables
    Number of Products under Development for Mantle Cell Lymphoma, H1 2015 15
    Number of Products under Development for Mantle Cell Lymphoma-Comparative Analysis, H1 2015 16
    Number of Products under Development by Companies, H1 2015 18
    Number of Products under Development by Companies, H1 2015 (Contd..1) 19
    Number of Products under Development by Companies, H1 2015 (Contd..2) 20
    Number of Products under Investigation by Universities/Institutes, H1 2015 21
    Comparative Analysis by Late Stage Development, H1 2015 22
    Comparative Analysis by Clinical Stage Development, H1 2015 23
    Comparative Analysis by Early Stage Development, H1 2015 24
    Products under Development by Companies, H1 2015 25
    Products under Development by Companies, H1 2015 (Contd..1) 26
    Products under Development by Companies, H1 2015 (Contd..2) 27
    Products under Development by Companies, H1 2015 (Contd..3) 28
    Products under Investigation by Universities/Institutes, H1 2015 29
    Mantle Cell Lymphoma-Pipeline by AbbVie Inc., H1 2015 30
    Mantle Cell Lymphoma-Pipeline by Accentia Biopharmaceuticals, Inc., H1 2015 31
    Mantle Cell Lymphoma-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 32
    Mantle Cell Lymphoma-Pipeline by Advancell, H1 2015 33
    Mantle Cell Lymphoma-Pipeline by Affimed Therapeutics AG, H1 2015 34
    Mantle Cell Lymphoma-Pipeline by Amgen Inc., H1 2015 35
    Mantle Cell Lymphoma-Pipeline by Astellas Pharma Inc., H1 2015 36
    Mantle Cell Lymphoma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 37
    Mantle Cell Lymphoma-Pipeline by Bayer AG, H1 2015 38
    Mantle Cell Lymphoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 39
    Mantle Cell Lymphoma-Pipeline by Celgene Corporation, H1 2015 40
    Mantle Cell Lymphoma-Pipeline by Celldex Therapeutics, Inc., H1 2015 41
    Mantle Cell Lymphoma-Pipeline by Eisai Co., Ltd., H1 2015 42
    Mantle Cell Lymphoma-Pipeline by Eli Lilly and Company, H1 2015 43
    Mantle Cell Lymphoma-Pipeline by EpiZyme, Inc., H1 2015 44
    Mantle Cell Lymphoma-Pipeline by Gilead Sciences, Inc., H1 2015 45
    Mantle Cell Lymphoma-Pipeline by GlaxoSmithKline plc, H1 2015 46
    Mantle Cell Lymphoma-Pipeline by ImmunoGen, Inc., H1 2015 47
    Mantle Cell Lymphoma-Pipeline by Incyte Corporation, H1 2015 48
    Mantle Cell Lymphoma-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 49
    Mantle Cell Lymphoma-Pipeline by Johnson & Johnson, H1 2015 50
    Mantle Cell Lymphoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 51
    Mantle Cell Lymphoma-Pipeline by Kite Pharma, Inc., H1 2015 52
    Mantle Cell Lymphoma-Pipeline by MedImmune, LLC, H1 2015 53
    Mantle Cell Lymphoma-Pipeline by Merck & Co., Inc., H1 2015 54
    Mantle Cell Lymphoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 55
    Mantle Cell Lymphoma-Pipeline by MorphoSys AG, H1 2015 56
    Mantle Cell Lymphoma-Pipeline by Nordic Nanovector AS, H1 2015 57
    Mantle Cell Lymphoma-Pipeline by Novartis AG, H1 2015 58
    Mantle Cell Lymphoma-Pipeline by Onconova Therapeutics, Inc., H1 2015 59
    Mantle Cell Lymphoma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 60
    Mantle Cell Lymphoma-Pipeline by Pfizer Inc., H1 2015 61
    Mantle Cell Lymphoma-Pipeline by Pharmacyclics, Inc., H1 2015 62
    Mantle Cell Lymphoma-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 63
    Mantle Cell Lymphoma-Pipeline by Seattle Genetics, Inc., H1 2015 64
    Mantle Cell Lymphoma-Pipeline by Sevion Therapeutics, Inc., H1 2015 65
    Mantle Cell Lymphoma-Pipeline by Stemline Therapeutics, Inc., H1 2015 66
    Mantle Cell Lymphoma-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 67
    Mantle Cell Lymphoma-Pipeline by TG Therapeutics, Inc., H1 2015 68
    Assessment by Monotherapy Products, H1 2015 69
    Assessment by Combination Products, H1 2015 70
    Number of Products by Stage and Target, H1 2015 72
    Number of Products by Stage and Mechanism of Action, H1 2015 75
    Number of Products by Stage and Route of Administration, H1 2015 78
    Number of Products by Stage and Molecule Type, H1 2015 80
    Mantle Cell Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 214
    Mantle Cell Lymphoma-Dormant Projects, H1 2015 319
    Mantle Cell Lymphoma-Dormant Projects (Contd..1), H1 2015 320
    Mantle Cell Lymphoma-Discontinued Products, H1 2015 321

    List of Figures
    Number of Products under Development for Mantle Cell Lymphoma, H1 2015 15
    Number of Products under Development for Mantle Cell Lymphoma-Comparative Analysis, H1 2015 16
    Number of Products under Development by Companies, H1 2015 17
    Number of Products under Investigation by Universities/Institutes, H1 2015 21
    Comparative Analysis by Clinical Stage Development, H1 2015 23
    Comparative Analysis by Early Stage Products, H1 2015 24
    Assessment by Monotherapy Products, H1 2015 69
    Number of Products by Top 10 Targets, H1 2015 71
    Number of Products by Stage and Top 10 Targets, H1 2015 71
    Number of Products by Top 10 Mechanism of Actions, H1 2015 74
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 74
    Number of Products by Top 10 Routes of Administration, H1 2015 77
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 77
    Number of Products by Top 10 Molecule Types, H1 2015 79
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 79
    AbbVie Inc.
    Accentia Biopharmaceuticals, Inc.
    Actinium Pharmaceuticals, Inc.
    Advancell
    Affimed Therapeutics AG
    Amgen Inc.
    Astellas Pharma Inc.
    Astex Pharmaceuticals, Inc.
    Bayer AG
    Bristol-Myers Squibb Company
    Celgene Corporation
    Celldex Therapeutics, Inc.
    Eisai Co., Ltd.
    Eli Lilly and Company
    EpiZyme, Inc.
    Gilead Sciences, Inc.
    GlaxoSmithKline plc
    ImmunoGen, Inc.
    Incyte Corporation
    Infinity Pharmaceuticals, Inc.
    Johnson & Johnson
    Karyopharm Therapeutics, Inc.
    Kite Pharma, Inc.
    MedImmune, LLC
    Merck & Co., Inc.
    Millennium Pharmaceuticals, Inc.
    MorphoSys AG
    Nordic Nanovector AS
    Novartis AG
    Onconova Therapeutics, Inc.
    Onyx Pharmaceuticals, Inc.
    Pfizer Inc.
    Pharmacyclics, Inc.
    Portola Pharmaceuticals, Inc.
    Seattle Genetics, Inc.
    Sevion Therapeutics, Inc.
    Stemline Therapeutics, Inc.
    Teva Pharmaceutical Industries Limited
    TG Therapeutics, Inc.

    Request for Sample

    Report Url https://www.reportsweb.com//mantle-cell-lymphoma-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//mantle-cell-lymphoma-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//mantle-cell-lymphoma-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments